These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8898542)

  • 21. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.
    Ozick LA; Jacob L; Comer GM; Lee TP; Ben-Zvi J; Donelson SS; Felton CP
    Am J Gastroenterol; 1995 Nov; 90(11):1978-80. PubMed ID: 7485004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatotoxicity of isoniazid and rifampin in children.
    Rugmini PS; Mehta S
    Indian Pediatr; 1984 Feb; 21(2):119-26. PubMed ID: 6469294
    [No Abstract]   [Full Text] [Related]  

  • 24. Liver injury during antituberculosis treatment: an 11-year study.
    Døssing M; Wilcke JT; Askgaard DS; Nybo B
    Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence].
    Moitinho E; Salmerón JM; Mas A; Bruguera M; Rodés J
    Gastroenterol Hepatol; 1996 Nov; 19(9):448-51. PubMed ID: 8998667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
    Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
    J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinically apparent liver damage during brief tuberculosis therapy].
    Estay S; Armas Merino R; Vega C; Soto JR
    Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
    [No Abstract]   [Full Text] [Related]  

  • 28. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
    Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
    Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hydrazide-rifampicin: hepatotoxicity in children].
    Uriz Urzainqui S; Masvidal Aliberch RM; Sabriá Pau J; Bofill Bernaldo AM
    An Esp Pediatr; 1981 Oct; 15(4):401-3. PubMed ID: 7337305
    [No Abstract]   [Full Text] [Related]  

  • 30. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.
    Martinez-Roíg A; Camí J; Llorens-Terol J; de la Torre R; Perich F
    Pediatrics; 1986 Jun; 77(6):912-5. PubMed ID: 3487069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatotoxicity caused by the combined action of isoniazid and rifampicin.
    Askgaard DS; Wilcke T; Døssing M
    Thorax; 1995 Feb; 50(2):213-4. PubMed ID: 7701468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hepatotoxic side-effects of rifampicin; a comparative clinical study (author's transl)].
    Kuntz HD; Rausch V
    Prax Klin Pneumol; 1977 Nov; 31(11):925-32. PubMed ID: 928291
    [No Abstract]   [Full Text] [Related]  

  • 33. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction.
    Pessayre D; Bentata M; Degott C; Nouel O; Miguet JP; Rueff B; Benhamou JP
    Gastroenterology; 1977 Feb; 72(2):284-9. PubMed ID: 830577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Antitubercular drug-induced liver injuries].
    Guo Y; Cui D
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 May; 21(5):308-9. PubMed ID: 11326960
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of tuberculous meningitis in adults: current trends and problems].
    Gallofre López M; Latorre Murillo P; Massons Cirera J; Sumalla Suñe J
    Rev Clin Esp; 1982 Sep; 166(6):317-9. PubMed ID: 6758078
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients.
    Thomas PA; Mozes MF; Jonasson O
    Arch Surg; 1979 May; 114(5):597-9. PubMed ID: 375876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis].
    Martínez Alfaro E; Solera J; Serna E; Cuenca D; Castillejos ML; Espinosa A; Sáez L
    Med Clin (Barc); 1998 Oct; 111(11):401-4. PubMed ID: 9834911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity.
    Lobato MN; Jereb JA; Starke JR
    Pediatrics; 2008 Jun; 121(6):e1732-3. PubMed ID: 18474531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
    Li F; Lu J; Cheng J; Wang L; Matsubara T; Csanaky IL; Klaassen CD; Gonzalez FJ; Ma X
    Nat Med; 2013 Apr; 19(4):418-20. PubMed ID: 23475203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.